-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Tl8P3e3VwFifzC5myNutU8oiDoZWmqD3LuapTeULzHq4uwKFRd9apy2ZdK9Pvtt1 yR4B4mymstbs6WQmZzjZQg== 0000950134-09-000657.txt : 20090116 0000950134-09-000657.hdr.sgml : 20090116 20090116165151 ACCESSION NUMBER: 0000950134-09-000657 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090114 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090116 DATE AS OF CHANGE: 20090116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XENOPORT INC CENTRAL INDEX KEY: 0001130591 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943330837 STATE OF INCORPORATION: DE FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51329 FILM NUMBER: 09532092 BUSINESS ADDRESS: STREET 1: 3410 CENTRAL EXPRESSWAY CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: 4086167200 MAIL ADDRESS: STREET 1: 3410 CENTRAL EXPRESSWAY CITY: SANTA CLARA STATE: CA ZIP: 95051 8-K 1 f51118e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 14, 2009
XENOPORT, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
     
000-51329   94-3330837
(Commission File No.)   (IRS Employer Identification No.)
3410 Central Expressway
Santa Clara, California 95051

(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (408) 616-7200
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Section 5 — Corporate Governance and Management
Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)   2008 Bonuses for Named Executive Officers
In January 2007, upon the recommendation of the compensation committee (the “Compensation Committee”) of the board of directors of XenoPort, Inc. (the “Company”), the board of directors of the Company (the “Board of Directors”) approved the XenoPort, Inc. Corporate Bonus Plan (the “Bonus Plan”). The purpose of the Bonus Plan is to: provide certain employees of the Company with incentives to achieve the highest level of individual and team performance and to meet or exceed specified goals, which contribute to the overall success of the Company; motivate participants to achieve both individual and Company objectives; and enable the Company to attract and retain high-quality employees. To date, the Company has paid annual bonus awards under the Bonus Plan in the form of cash payments.
On January 14, 2009, the Board approved, upon the recommendation of the Compensation Committee, bonus awards under the Bonus Plan for the 2008 performance period for the Company’s “named executive officers” (as defined under applicable securities laws). Consistent with the Company’s efforts to preserve cash, the Board approved, upon the recommendation of the Compensation Committee, and the Company’s executives agreed, that such 2008 bonus awards would be paid in restricted stock units (“RSUs”) pursuant to the Company’s 2005 Equity Incentive Plan in lieu of cash payments. The RSUs granted in lieu of cash bonus payments are immediately vested, may be settled in stock and were granted at $26.97 per share based on the closing trading price of the Company’s common stock on the Nasdaq Global Select Market on January 14, 2009. The RSUs granted in lieu of cash payments under the Bonus Plan for the 2008 performance period represent settlement in full of the Company’s cash award obligations, if any, to such individuals under the Bonus Plan for the 2008 performance period. The 2008 bonus information for the named executive officers is set forth on Exhibit 10.25.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01   Financial Statements and Exhibits.
     
Exhibit   Description
 
   
10.25.1
  2008 Executive Compensation Bonus Information

 


 

Signatures
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  XenoPort, Inc.
(Registrant)
 
 
Dated: January 16, 2009  By:   /s/ William G. Harris    
    William G. Harris   
    Senior Vice President of Finance and Chief
Financial Officer 
 
 

 


 

Exhibit Index
     
Exhibit   Description
 
   
10.25.1
  2008 Executive Compensation Bonus Information

 

EX-10.25.1 2 f51118exv10w25w1.htm EX-10.25.1 exv10w25w1
Exhibit 10.25.1
Named Executive Officer Compensation Information — 2008 Bonus Awards
The table below provides information regarding the RSUs granted to the Company’s named executive officers in lieu of cash payments under the Bonus Plan for the 2008 performance period:
                 
    Value of Cash   RSU Equivalent
Named Executive Officer   Bonus Award (1)   Grant (2)
Ronald W. Barrett, PhD
  $ 266,250.00       9,872  
Chief Executive Officer
               
William G. Harris
  $ 82,687.50       3,065  
Senior Vice President of Finance and Chief Financial Officer
               
William J. Rieflin
  $ 150,820.31       5,592  
President
               
Kenneth C. Cundy, PhD
  $ 83,737.50       3,104  
Senior Vice President of Preclinical Development
               
David R. Savello, PhD
  $ 81,600.00       3,025  
Senior Vice President of Development
               
 
(1)   Cash Bonus Award amounts determined under the Bonus Plan for the 2008 performance period.
 
(2)   RSUs granted pursuant to the 2005 Equity Incentive Plan at the close of trading on January 14, 2009 at $26.97 per share (the closing stock price of the Company’s common stock on the Nasdaq Global Select Market), rounded down to the nearest whole share (no fractional shares were issued). The RSUs, which may be settled in stock, are immediately vested in full at the time of grant.

 

-----END PRIVACY-ENHANCED MESSAGE-----